Biotechnology equities are slumping to start 2021, with the S&P Biotechnology Select Industry Index down 10% year-to-date. Mergers and acquisitions activity, which are typically vibrant in the biotech space, are also in a funk. Yet many experts believe biotech consolidation is poised to pick up...